Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914971 | 0.90 | CCR5 (0.35) | CCR5CXCR4 | |
| Benzamide SCHEMBL4042439 | 0.89 | CCR5 (0.37) | CCR5KCNH2 | |
| SCHEMBL4032617 | 0.83 | ALDH1A1 (0.41) | CCR5ALDH1A1 | |
| SCHEMBL3926289 | 0.81 | CCR5 (0.33) | CCR5CXCR4KMT2A | |
| SCHEMBL1799699 | 0.80 | CCR5 (0.44) | CCR5ALDH1A1KMT2A | |
| SCHEMBL1801164 | 0.80 | NPC1 (0.45) | CCR5ALDH1A1LMNAKMT2A | |
| SCHEMBL3920466 | 0.79 | POLB (0.42) | CCR5CXCR4ALDH1A1LMNAKMT2A | |
| SCHEMBL3915084 | 0.79 | CCR5 (0.32) | CCR5 | |
| SCHEMBL1803504 | 0.79 | POLB (0.41) | ALDH1A1KMT2A | |
| SCHEMBL4038217 | 0.78 | CCR5 (0.32) | CCR5CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | claimed |
| EP-1730144-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | CCR5 2852/4885CXCR4 2135/4885ALDH1A1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.